Adbry access in the United Arab Emirates: the EDE named-patient pathway

Last reviewed 2026-05-12 by the Reserve Meds clinical and regulatory team. This page combines the UAE country research module with the Adbry drug module to describe the path families actually walk.

Quick orientation

Adbry (tralokinumab-ldrm) is a fully human IgG4 monoclonal antibody that selectively neutralises interleukin-13, manufactured by LEO Pharma. The US Food and Drug Administration approved Adbry in December 2021 for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The same molecule is marketed as Adtralza in the European Union, the United Kingdom, Canada, and selected Gulf markets. Dosing is a 600 mg loading dose (four 150 mg subcutaneous injections), then 300 mg every two weeks. Adbry is a refrigerated biologic. Reserved for you.

Why UAE patients need Adbry via a named-patient pathway

Atopic dermatitis is well represented across the UAE patient population, with prevalence consistent with regional GCC dermatology cohorts. The first-line biologic in most UAE dermatology practices is dupilumab, which holds an established MoHAP registration and is widely stocked. Adbry's clinical position is the next-line IL-13-selective option for adults who either did not achieve adequate clearance on dupilumab, lost response over time, or experienced an adverse event such as conjunctivitis or injection-site reactions that limits continued IL-4/IL-13 dual blockade. The UAE market currently does not maintain a federal Adbry stock at the consistent level that dupilumab enjoys, and dermatologists who reach for the IL-13-selective mechanism typically work through a named-patient import.

The access gap is therefore not a regulatory ceiling. The EDE named-patient pathway is designed exactly for this situation: a US-approved biologic with a defined clinical role, no locally registered direct equivalent at the IL-13-selective mechanism level, and a treating physician prepared to document why this specific molecule is the right next move for this specific patient.

The EDE / MoHAP named-patient pathway applied to Adbry

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered or not stocked locally is the unregistered-medicine import permit, administered through the Emirates Drug Establishment (EDE) at ede.gov.ae. The EDE took over 44 core services from MoHAP under Federal Decree-Law No. 38 of 2024 on 29 December 2025. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority such as the US FDA and a locally registered alternative is not suitable.

For Adbry, the clinical justification packet is more straightforward than for a gene therapy or oncology case. The treating dermatologist documents the patient's atopic dermatitis severity scores (EASI, IGA, body surface area involvement, sleep and pruritus impact), prior topical therapy regimen and outcomes (medium-to-high-potency topical corticosteroids, calcineurin inhibitors), phototherapy where attempted, and the specific outcome on dupilumab if trialled, including any adverse event that limited continuation. The letter explains why IL-13-selective blockade is the appropriate next step and references the LEO Pharma US label.

A complete EDE application for Adbry typically includes the dermatologist's clinical justification letter, the treating physician's MoHAP, DHA, DoH, or Sharjah Health Authority licence verification, an anonymised patient identifier, full product details (Adbry 150 mg/mL prefilled syringe), the destination dispensing facility name with licence number and pharmacy in charge, the cold-chain handling plan, and the patient informed consent. Approval timelines for routine cases are 5 to 15 business days. Complex submissions extend to 4 to 6 weeks. For Adbry, most submissions fall in the routine band because the molecule has a clear FDA approval, a defined clinical role, and a documented adverse-event profile.

Where Adbry gets dispensed in the UAE

Adbry ships as a 150 mg/mL prefilled syringe and must be stored refrigerated at 2 to 8 degrees Celsius. After arrival in the UAE, dispensing happens through a licensed pharmaceutical establishment attached to the treating dermatology clinic or hospital. The most natural dispensing sites for Adbry cases are dermatology departments at American Hospital Dubai, Mediclinic City Hospital in Dubai Healthcare City, Cleveland Clinic Abu Dhabi, NMC Royal Hospital in Khalifa City, and Sheikh Khalifa Medical City. The drug can also be dispensed through specialty dermatology clinics where the consulting dermatologist holds active emirate licensure and the attached pharmacy holds the establishment licence the EDE recognises.

The first dose can be administered in the clinic so the dermatology team observes the loading injection set. Once the patient has completed loading and tolerated the every-two-week schedule, many UAE dermatologists transition the patient to home self-administration with a structured cold-chain handoff. Reserve Meds does not select the dispensing facility on the patient's behalf. We coordinate the regulatory documentation and the logistics; the treating dermatologist and the family pick the clinic.

Real cost picture for Adbry in the UAE

The US wholesale acquisition cost for Adbry is approximately USD 3,500 to 4,000 per 300 mg dose (two 150 mg prefilled syringes), which translates to approximately USD 7,000 to 8,000 for the four-syringe 600 mg loading dose and approximately USD 7,000 to 9,000 monthly thereafter at the every-two-week maintenance schedule. In AED at the 3.67 peg, monthly maintenance is approximately AED 26,000 to 33,000.

All-in delivered cost for a UAE patient on Adbry stacks the drug acquisition cost, refrigerated international logistics (approximately USD 800 to 1,500 per shipment depending on shipment size and route), the EDE handling and customs clearance fees (typically USD 300 to 600 per case), the dispensing pharmacy's handling fee, and the Reserve Meds concierge coordination fee. We quote each case after the documentation review so the patient sees a firm range before any wire. Insurance in the UAE handles atopic-dermatitis biologic cases case by case. Thiqa, administered by Daman for UAE nationals in Abu Dhabi, has the broadest specialty coverage. Daman, GIG Gulf, Sukoon, ADNIC, and Orient each pre-authorise specialty biologics. We supply the documentation set that lets your insurer assess the case. We do not promise coverage from any insurer.

Typical timeline for Adbry in the UAE

The EDE permit is the gating regulatory step. Routine submissions for a US-approved biologic with a clear clinical role process in 5 to 15 business days from a complete file. Once the permit is in hand, refrigerated logistics from the US to the UAE add approximately 5 to 10 business days. Customs clearance at Dubai International or Abu Dhabi International typically completes within 1 to 3 business days when the documentation is clean. Dispensing pharmacy handover and the patient's first loading injection follows immediately. A patient who completes the documentation in week one typically receives the first dose in week four to week six. Reserve Meds frames the case as a coordinated four-to-six-week onboarding rather than a same-week ship.

What your physician needs to provide

The clinical justification letter for an Adbry EDE submission is shorter and more pattern-matched than for a novel therapy. The treating dermatologist's letter typically addresses the diagnosis (chronic moderate-to-severe atopic dermatitis), severity quantification (EASI, IGA, BSA, sleep and itch impact), prior therapy trail (topical corticosteroids of medium-to-high potency, topical calcineurin inhibitors, phototherapy where attempted), dupilumab outcome where trialled (efficacy, adverse events such as conjunctivitis or injection-site reaction, time to loss of response), and the rationale for IL-13-selective blockade now. The letter typically references the LEO Pharma US label and the every-two-week 300 mg maintenance schedule after the 600 mg loading dose.

The treating physician's licence must be in active standing in the emirate of the dispensing facility (MoHAP for the Northern Emirates, DHA for Dubai, DoH for Abu Dhabi and Al Ain, Sharjah Health Authority for Sharjah). The patient signs informed consent for the named-patient route and for the cold-chain receipt protocol. The pharmacy in charge at the dispensing facility holds the establishment licence the EDE verifies at submission.

Pharmacovigilance and cold-chain considerations

Adbry is a refrigerated biologic. The shipment chain runs 2 to 8 degrees Celsius from the US manufacturer's specialty distributor to the UAE dispensing pharmacy. Each shipment carries calibrated temperature monitors and a chain-of-custody log. On arrival at the dispensing facility, the pharmacy in charge confirms the temperature record before release. The patient receives a brief cold-chain handling primer when transitioning to home self-administration: refrigerator storage, not freezer, and a 14-day room-temperature stability allowance for travel use as documented in the US label. Pharmacovigilance follow-up after dose one and dose four is standard. Adverse events identified by the treating dermatologist route to LEO Pharma's safety reporting channel and to the EDE post-market surveillance address.

Common questions about Adbry in the UAE

Why Adbry rather than dupilumab? Dupilumab remains the first-line biologic for moderate-to-severe atopic dermatitis in most UAE dermatology practices because it holds an established MoHAP registration, is widely stocked, and has the longer real-world experience. The case for Adbry is built when dupilumab has been trialled and the patient either did not achieve adequate clearance, lost response, or experienced a limiting adverse event such as conjunctivitis. The clinical choice rests with the treating dermatologist.

Will Daman, Thiqa, or my private insurer cover this? Each insurer assesses specialty biologic cases case by case. Pre-authorisation is the norm. Thiqa, the government-funded programme for UAE nationals administered by Daman, has the broadest specialty coverage in Abu Dhabi. We supply the documentation set that lets your insurer assess the case. We do not promise coverage from any insurer.

Is Adbry a controlled substance? No. Adbry is not a DEA scheduled substance. The federal narcotics framework does not apply. The cold-chain documentation and the dispensing pharmacy's establishment licence are verified at the EDE step.

Can I self-administer Adbry at home? After the loading set in the clinic and once the patient has tolerated the every-two-week schedule, many UAE dermatologists transition Adbry patients to home self-administration. A short clinic training visit covers prefilled-syringe handling and refrigerated storage.

What patients ask when they first call

"How does the case actually start?" The patient or the treating dermatologist contacts Reserve Meds through the waitlist form. Within 24 to 48 hours, a coordinator confirms eligibility, sends the documentation kit to the physician, and outlines the EDE submission sequence. The patient does not pay anything at this stage. The firm quote follows once the documentation is reviewed and the EDE pathway is confirmed.

"Who actually receives the syringes when they land in the UAE?" The dispensing pharmacy attached to the treating dermatology clinic is the named recipient on the EDE permit. The pharmacy in charge signs for the shipment, confirms the cold-chain temperature record, and dispenses to the patient with the dermatologist's prescription on file. The Reserve Meds coordinator confirms the handoff and stays with the patient through the first injection.

"What happens if the EDE permit takes longer than expected?" Routine submissions for Adbry fall in the 5-to-15 business-day band the EDE publishes. If a submission falls in the complex band (4 to 6 weeks), the coordinator confirms the cause (typically a clarification request from the EDE review team) and updates the timeline before any drug procurement step is triggered. The patient does not wire for drug procurement until the permit is in hand and the procurement step is the next operational item.

"What if I move between emirates during therapy?" Most UAE Adbry patients stay with one dispensing dermatology clinic for the duration of therapy. If a patient relocates between emirates, the dispensing transfer is handled by adding a second dispensing site under the treating physician's coordination. The coordinator manages the supply continuity.

Where Reserve Meds fits in Adbry cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating dermatologist, the EDE, or the dispensing pharmacy. For an Adbry case, our work is the regulatory documentation assembly, the US-side procurement coordination with the LEO Pharma specialty distributor, the refrigerated logistics, the customs handoff, and a single named coordinator for the patient through the four-to-six-week onboarding window. We hold the cold chain end to end and we hand the prefilled syringes to the dispensing pharmacy in the temperature record the EDE expects. Reserved for you.

Documentation kit for the treating dermatologist

The documentation kit Reserve Meds sends the treating dermatologist after a waitlist confirmation contains the EDE clinical-justification letter template tailored to the IL-13-selective biologic class, the dupilumab-trial outcome capture sheet, the EASI and IGA tracking template, the patient informed consent template covering the named-patient route and the cold-chain receipt protocol, the dispensing pharmacy intake checklist, the cold-chain receipt log, the home self-administration patient handout, and the post-first-dose follow-up template. The kit is built so the dermatologist's clinic spends minimum time on form work and maximum time on the clinical assessment that anchors the EDE submission. The clinic can use the kit as templates or as starting points for their own existing documentation.

Next step

If a treating dermatologist in the UAE is weighing Adbry for an adult patient, the waitlist is the first step. We respond within 24 to 48 hours with an eligibility confirmation and a documentation kit for the physician.

Join the Adbry waitlist

Reserved for you.

Related

• Adbry clinical resource
• Atopic dermatitis
• United Arab Emirates country page
• Named-patient pathway overview

Sources

1. FDA approval, Adbry (tralokinumab-ldrm), LEO Pharma, BLA approval December 2021 for moderate-to-severe atopic dermatitis in adults.
2. UAE Federal Decree-Law No. 38 of 2024 and the Emirates Drug Establishment portal at ede.gov.ae; MoHAP Issue of Permit to Import Medicines for Personal Use.
3. LEO Pharma US prescribing information for Adbry, 150 mg/mL prefilled syringe, refrigerated 2 to 8 d